Comparison of a gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare-up regimen in poor responders undergoing ovarian stimulation 

Slides:



Advertisements
Similar presentations
The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis 
Advertisements

Comparison of FSH flare with and without pretreatment with oral contraceptive pills in poor responders undergoing in vitro fertilization  Martin D. Keltz,
Antagonists in poor-responder patients
Is the type of gonadotropin-releasing hormone suppression protocol for ovarian hyperstimulation associated with ectopic pregnancy in fresh autologous.
Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study  Thi.
Soyoung Bae, M.D., Joseph Karnitis, M.D.  Fertility and Sterility 
Impact of endogenous luteinizing hormone serum levels on progesterone elevation on the day of human chorionic gonadotropin administration  Jean-noêl Hugues,
Gonadotropin-releasing hormone agonist trigger increases the number of oocytes and embryos available for cryopreservation in cancer patients undergoing.
Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective,
Does the time interval between antimüllerian hormone serum sampling and initiation of ovarian stimulation affect its predictive ability in in vitro fertilization–intracytoplasmic.
Fernando Zegers-Hochschild, M.D.  Fertility and Sterility 
Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor.
Michael M. Alper, M.D.  Fertility and Sterility 
Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.
Follicular fluid anti-Müllerian hormone and inhibin B concentrations: comparison between gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist.
Ovarian pregnancy after in vitro fertilization
Cem Atabekoglu, M. D. , Murat Sonmezer, M. D. , Sinan Özkavukcu, M. D
Early loss rates of entire pregnancies after assisted reproduction are lower in twin than in singleton pregnancies  Alexandra Matias, M.D., Giovanni B.
Medical treatment of ectopic pregnancy: a committee opinion
Hakan Cakmak, M. D. , Audra Katz, R. N. , Marcelle I. Cedars, M. D
Postoperative medical treatment of chronic pelvic pain related to severe endometriosis: levonorgestrel-releasing intrauterine system versus gonadotropin-releasing.
Grant D.E. McWilliams, D.O., John L. Frattarelli, M.D. 
How old is too old? Challenges faced by clinicians concerning age cutoffs for patients undergoing in vitro fertilization  Robert L. Klitzman, M.D.  Fertility.
The role of steroid hormone supplementation in non–assisted reproductive technology treatments for unexplained infertility  Alexander M. Quaas, M.D.,
Subtle progesterone rise on the day of human chorionic gonadotropin administration is associated with lower live birth rates in women undergoing assisted.
Oocyte cryopreservation
Establishing a human chorionic gonadotropin cutoff to guide methotrexate treatment of ectopic pregnancy: a systematic review  Seema Menon, M.D., John.
Robert F. Casper, M.D.  Fertility and Sterility 
Treatment with leuprolide acetate and hormonal add-back for up to 10 years in stage IV endometriosis patients with chronic pelvic pain  Mohamed A. Bedaiwy,
Impact of luteal phase support on pregnancy rates in intrauterine insemination cycles: a prospective randomized study  Ahmet Erdem, M.D., Mehmet Erdem,
Influence of acupuncture stimulation on pregnancy rates for women undergoing embryo transfer  Caroline Smith, Ph.D., Meaghan Coyle, B.Hlth.Sc. (Acup.),
A comparison of three downregulation approaches for poor responders undergoing in vitro fertilization  Laura Detti, M.D., Daniel B. Williams, M.D., Jared.
Ultrashort flare gonadotropin-releasing hormone (GnRH) agonist/GnRH antagonist protocol: a valuable tool in the armamentarium of ovulation induction for.
Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose.
The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis 
How to improve the probability of pregnancy in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis  Dimitra Kyrou,
Management of tubal ectopic pregnancy: methotrexate and salpingostomy are preferred to preserve fertility  Stephanie Beall, M.D., Ph.D., Alan H. DeCherney,
Clomiphene citrate at 50: the dawning of assisted reproduction
Treatment of Ovarian Hyperstimulation Syndrome Utilizing a Dopamine Agonist and Gonadotropin Releasing Hormone antagonist  N. Rollene, M. Amols, S. Hudson,
Akanksha Mehta, M.D., Darius A. Paduch, M.D., Ph.D. 
Antonio La Marca, M. D. , Simone Giulini, M. D. , Giovanni Vito, M. D
Gonadotropin-releasing hormone antagonist use is associated with increased pregnancy rates in ovulation induction–intrauterine insemination to in vitro.
Changes in cytokine levels of patients with ovarian endometriosis after treatment with gonadotropin-releasing hormone analogue, ultrasound-guided drainage,
Number of good quality embryos on day 3 is predictive for both pregnancy and implantation rates in in vitro fertilization/intracytoplasmic sperm injection.
Clinical and endocrine response to the withdrawal of gonadotropin-releasing hormone agonists during prolonged coasting  Basil Ho Yuen, M.B., Ch.B., Tuan-Anh.
Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series  Nanette L. Rollene,
Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis.
Effect of gonadotropin-releasing-hormone-induced hypogonadism on insulin action as assessed by euglycemic clamp studies in men  Subodhsingh Chauhan, M.D.,
Reducing the dose of human chorionic gonadotropin in high responders does not affect the outcomes of in vitro fertilization  David W. Schmidt, M.D.,,
Fertility and Sterility: an evaluation
Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing.
Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin.
Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis  Ernesto Bosch, M.D., Elena.
Effects of gonadotropin-releasing hormone agonist/recombinant follicle-stimulating hormone versus gonadotropin-releasing hormone antagonist/recombinant.
Cost-effectiveness comparison between pituitary down-regulation with a gonadotropin- releasing hormone agonist short regimen on alternate days and an antagonist.
Eric S. Surrey, M. D. , Debra A. Minjarez, M. D. , John M. Stevens, B
Fertility and Sterility
Evaluating the role of exogenous luteinizing hormone in poor responders undergoing in vitro fertilization with gonadotropin-releasing hormone antagonists 
Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study  Ahmed Badawy, M.D., Aboubakr.
Egg production predicts a doubling of in vitro fertilization pregnancy rates even within defined age and ovarian reserve categories  Melissa C. Yih, M.D.,
Cem Fiçicioǧlu, M. D. , Tayfun Kutlu, M. D. , Elif Baglam, M. D
In vitro sildenafil citrate use as a sperm motility stimulant
Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles 
A novel “delayed start” protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders  Hakan Cakmak, M.D., Nam D. Tran,
A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for.
Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing.
In vitro viability and secretory capacity of human luteinized granulosa cells after gonadotropin-releasing hormone agonist trigger of oocyte maturation 
Serum anti-müllerian hormone levels in women with secondary amenorrhea
Comparisons of inhibin B versus antimüllerian hormone in poor ovarian responders undergoing in vitro fertilization  Rongrong Tan, M.M.Sc., Danhua Pu,
Use of progestins to inhibit spontaneous ovulation during ovarian stimulation: the beginning of a new era?  Antonio La Marca, Martina Capuzzo  Reproductive.
Presentation transcript:

Comparison of a gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare-up regimen in poor responders undergoing ovarian stimulation  Stefania Malmusi, M.D., Antonio La Marca, M.D., Simone Giulini, M.D., Susanna Xella, B.D., Daniela Tagliasacchi, B.D., Tiziana Marsella, B.D., Annibale Volpe, M.D.  Fertility and Sterility  Volume 84, Issue 2, Pages 402-406 (August 2005) DOI: 10.1016/j.fertnstert.2005.01.139 Copyright © 2005 American Society for Reproductive Medicine Terms and Conditions

FIGURE 1 Fertilization (FR), implantation (IR), and pregnancy rates (PR) in GnRH-a and GnRH-antagonist groups. Red bars, GnRH-a; yellow bars, GnRH antagonist. *P<.01. Malmusi. GnRH antagonist and GnRH agonist in ovarian stimulation. Fertil Steril 2005. Fertility and Sterility 2005 84, 402-406DOI: (10.1016/j.fertnstert.2005.01.139) Copyright © 2005 American Society for Reproductive Medicine Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.